The Nanobodies market is estimated to be valued at US$ 368.6 Million In 2022 and is expected to exhibit a CAGR of 24.1% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Nanobodies are single domain antigen binding fragments derived from camelids, which include camels, llamas and alpacas. Nanobodies exhibit high affinity, specificity, thermostability. Due to their small size, nanobodies can bind epitopes that are difficult for regular antibody fragments to access. The unique properties of nanobodies make them suitable for various applications in research, diagnostics and therapeutics.

Market Dynamics:
The nanobodies market is driven by increasing demand from the healthcare industry for diagnosis and treatment of various diseases. Nanobodies can be used as an alternative to monoclonal antibodies in immunotherapy due to advantages such as small size, low cost production through microbial system. Advancements in recombinant DNA technologies have enabled large-scale production of nanobodies, thus fueling market growth. Nanobodies exhibit high stability at elevated temperatures, allowing their use in developing robust diagnostic tests. Their small size allows deeper tissue penetration compared to regular antibodies.

Read More : https://cmiorientedreportblog.blogspot.com/2023/11/nanobodies-market-is-estimated-to.html